Illustration of USC researchers preparing dopamine-producing stem cell implants for early-stage Parkinson’s trial.
Изображение, созданное ИИ

USC researchers begin early trial of dopamine-producing stem cell implants for Parkinson’s

Сообщено ИИ Изображение, созданное ИИ Проверено фактами

Keck Medicine of USC researchers are testing an experimental approach to Parkinson’s disease that implants lab-grown, dopamine-producing cells into a movement-control region of the brain. The early-stage Phase 1 REPLACE trial involves up to 12 people with moderate to moderate-severe Parkinson’s disease, and the U.S. Food and Drug Administration has granted the study fast-track designation.

An experimental oral pill called enlicitide lowered LDL cholesterol by about 60% in a large phase three clinical trial, according to results published in The New England Journal of Medicine. The trial, led by Dr. Ann Marie Navar at UT Southwestern Medical Center and sponsored by Merck, involved 2,909 participants mostly already on statins. If approved, the daily pill could improve access to effective cholesterol treatment.

Сообщено ИИ

Researchers tested a redesigned CD40 agonist antibody, 2141-V11, by injecting it directly into tumors of 12 patients with metastatic cancers. Six patients saw tumor shrinkage, with two achieving complete remission, including effects on untreated tumors elsewhere in the body. The trial reported only mild side effects, unlike prior CD40 therapies.

A large clinical trial has shown that the immunotherapy drug pembrolizumab may help prevent the deadly spread of Merkel cell carcinoma, a rare and aggressive skin cancer, after surgery. While it did not significantly reduce overall recurrence rates, the treatment lowered the risk of distant metastases by 42%. The findings offer hope for patients facing this fast-developing disease.

Сообщено ИИ

A Korean clinical trial has demonstrated that low-dose radiation therapy significantly reduces pain and improves mobility in patients with mild to moderate knee osteoarthritis, outperforming placebo effects. The treatment, which uses doses far below those for cancer, showed no side effects and could serve as an alternative to medications or surgery. Results were presented at the American Society for Radiation Oncology Annual Meeting.

Этот сайт использует куки

Мы используем куки для анализа, чтобы улучшить наш сайт. Прочитайте нашу политику конфиденциальности для дополнительной информации.
Отклонить